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BACKGROUND: The detection of circulating tumour cells (CTCs) has been linked with poor prognosis in advanced breast cancer.
Relatively few studies have been undertaken to study the clinical relevance of CTCs in early-stage breast cancer.
METHODS: In a prospective study, we evaluated CTCs in the peripheral blood of 82 early-stage breast cancer patients. Control groups
consisted of 16 advanced breast cancer patients and 45 healthy volunteers. The CTC detection was performed using ErbB2/EpCAM
immunomagnetic tumour cell enrichment followed by multimarker quantitative PCR (QPCR). The CTC status and common
clinicopathological factors were correlated to relapse-free, breast cancer-related and overall survival.
RESULTS: Circulating tumour cells were detected in 16 of 82 (20%) patients with early-stage breast cancer and in 13 out of 16 (81%)
with advanced breast cancer. The specificity was 100%. The median follow-up time was 51 months (range: 17–60). The CTC
positivity in early-stage breast cancer patients resulted in significantly poorer relapse-free survival (log rank test: P¼0.003) and was an
independent predictor of relapse-free survival (multivariate hazard ratio¼5.13, P¼0.006, 95% CI: 1.62–16.31).
CONCLUSION: The detection of CTCs in peripheral blood of early-stage breast cancer patients provided prognostic information for
relapse-free survival.
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Breast cancer mortality rates have declined over the last decade
because of better screening and improved diagnostic techniques
and treatments; however, it still remains the main cause of cancer-
related deaths in women worldwide (Levi et al, 2005). Approxi-
mately one-third of all women with primary breast cancer will
develop metastatic disease (Rosen et al, 1989; Fisher et al, 2002),
whereby the risk of relapse is strongly related to lymph node
involvement, tumour size, grade at diagnosis (Fitzgibbons et al,
2000), lymphatic and/or vascular invasion, hormone receptor
status and presence of HER2 overexpression (Pinder et al, 1994).
More recently, the risk of metastasis has also been shown to
correlate well with prognostic gene expression profiles (van de
Vijver et al, 2002; Paik et al, 2004; Wang et al, 2005).
The detection of circulating tumour cells (CTCs) has been
correlated to poor progression-free survival in patients with
metastatic breast cancer (Cristofanilli et al, 2004, 2005). For CTCs,
starting with peripheral blood as sampling material is advanta-
geous for the patient, as it is much less invasive to obtain than a
tumour biopsy. Moreover, the accessibility enables sequential
sampling during therapy. In patients with early-stage breast
cancer, the detection of CTCs or disseminated tumour cells
(DTCs) in the blood and/or bone marrow has also been found to
be an independent negative prognostic factor for disease
recurrence and overall survival (Mansi et al, 1999; Pantel et al,
1999; Braun et al, 2000). However, relatively few studies have been
undertaken to investigate the prognostic significance of CTCs in
non-metastatic breast cancer patients (Daskalaki et al, 2009;
Muller and Pantel, 2009; Xenidis et al, 2009), perhaps because of
the high assay sensitivity and specificity required for such studies
as a result of the relative rarity of CTCs.
Previously, we designed a quantitative PCR (QPCR)-based assay
that utilises a panel of four tumour marker genes for the detection
of occult tumour cells in the peripheral blood of metastatic breast
cancer patients. The tumour marker genes had been selected after
a systematic search for genes that are highly expressed in breast
cancer, but not in the cellular constituents of peripheral blood
(Bosma et al, 2002). Our test showed a sensitivity of 31% and a
specificity of 100% in metastatic breast cancer patients and
predicted for a worse progression-free and overall survival
(Weigelt et al, 2003). Next, we optimised the assay’s sensitivity
by introducing a dual-antigen immunomagnetic tumour cell
enrichment procedure before marker gene quantitation and by
refining the panel of marker genes as follows: cytokeratin 19
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s(CK19), human secretory protein p1.B (p1B), human epithelial
glycoprotein (EpCAM; here: EGP) and mammaglobin (MmGl)
(Molloy et al, 2008). In spiking experiments, we showed that our
assay has the sensitivity of detecting as few as 10 tumour cells from
a background of 10
6 peripheral blood mononuclear cells (PBMCs)
(Molloy et al, 2008).
In this study, we used our improved platform for CTC detection
in a prospective cohort of patients with early-stage breast cancer,
in an effort to detect the presence of CTCs at diagnosis. These data
were then correlated to disease outcome. In addition, we used our
platform in two control groups, being advanced breast cancer
patients and healthy volunteers.
MATERIALS AND METHODS
The methods and data described herein adhere to the REMARK
criteria for the reporting of tumour marker prognostic studies
(McShane et al, 2006).
Patient selection and peripheral blood sampling
Written informed consent was obtained from all participants and
the study was approved by the medical ethical committee of the
Netherlands Cancer Institute. Women presenting at the outpatient
clinic of The Netherlands Cancer Institute with clinically stage
I–III breast cancer were invited to participate between May 2005
and May 2006. Patients with a history of previous malignancy and
patients with disseminated breast cancer or active infection were
excluded. Type of surgery, locoregional radiotherapy and adjuvant
systemic therapy was left to the treating physician, following
nationwide standardised protocols.
From all patients, 8.0ml whole blood samples were collected
during routine preoperative blood sampling in tubes containing a
Ficoll-Hypaque density fluid separated by a polyester gel barrier
from a sodium citrate anticoagulant (Vacutainer CPT, Beckton
Dickinson, Breda, The Netherlands). Mononuclear cells, including
any tumour cells present, were isolated from blood samples within
24h of collection.
Selection of advanced breast cancer patients and healthy
volunteer control subjects
Patients with advanced breast cancer (M1 disease, according to the
Union Internationale Contre le Cancer criteria) were included as
‘positive controls’ as the majority were expected to have CTCs.
They were invited to participate if they were between treatments or
soon to start subsequent palliative treatment modality. Also, a
third group of healthy, female anonymous control subjects, who
were randomly selected from hospital staff, were asked to
participate. Blood sample collection and preparation were
performed as described above.
Additional analyses: effect of frozen storage and the value
of repeated sampling after therapy
In order to assess the effect of frozen storage, samples of a
subgroup of patients and healthy volunteers were collected in
duplicate. Mononuclear fractions were isolated and one sample
was analysed directly and the other was supplemented with
‘freezing medium’ (RPMI-1640 medium with L-glutamine (Gibco,
Breda, The Netherlands) containing 10% dimethylsulphoxide,
(DMSO; Merck, Darmstadt, Germany) and 20% fetal calf serum
(Gibco) and stored in liquid nitrogen. After 3 months, the frozen
pellets were thawed and enriched as described above.
In order to gain insight into the additional value of our assay
after therapy, peripheral blood samples were collected between
October 2008 and February 2009, after written informed consent,
from a subset of patients who continued to visit the outpatient
clinic and had remained disease free.
Tumour cell enrichment
Tumour cells were separated from PBMCs using anti-EpCAM
(CD326) (clone HEA-125) and anti-ErbB2 (HER2) Micro Beads
(MACS, Miltenyi Biotec, Utrecht, The Netherlands) according to
the manufacturer’s instructions. In brief, beads were incubated
with the PBMCs for 30min at 41C, after which labelled cells were
collected on a magnetic separation column. After removal of the
column from the magnetic field, the retained EpCAM
þ and/or
ErbB2
þ cells were eluted, and stored at  701C in lysis buffer (5 M
Guanidine thiocyanate (Merck), pH 6.8, 0.05 M Tris (Roche,
Mannheim, Germany), 0.02 M EDTA and 1.3% Triton X-100
(Sigma, Steinheim, Germany)) until mRNA isolation and cDNA
synthesis.
mRNA isolation and cDNA synthesis
mRNA was precipitated from the cell lysate and dissolved in lysis
buffer from the mMACS One-step cDNA kit (Miltenyi Biotec).
Oligo(dT) Micro Beads were added and the mixture placed onto
the mMACS column in the thermo MACS Separator. Next, cDNA
synthesis was carried out as per the manufacturer’s instructions,
with an additional elution with 20ml of elution buffer, resulting in a
total volume of 70ml.
Quantitative real-time PCR
Quantitative real-time PCR primers (Sigma Genosys, Cambridge,
UK) and 50-fluorescently FAM-labelled TaqMan probes (Applied
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) were
designed using the Perkin Elmer Primer Express software (PE,
Foster City, CA, USA) based on the published sequences of CK19,
p1B, EGP and MmGl as previously described (Molloy et al, 2008)
(Table 1). All primers were designed to be intron-spanning to
Table 1 Primer sequences
Gene
GenBank
accession Sequence Probe (50FAM–30TAMRA)
p1B L15203 Sense: CTGAGGAGTACGTGGGCCTG CTGCAAACCAGTGTGCCGTGCC
Antisense: AGTCCACCCTGTCCTTGGC
CK19 M002276 Sense: CTACAGCCACTACTACACGAC CACCATTGAGAACTCCAGGATTGTCCTGC
Antisense: CAGAGCCTGTTCCGTCTCAAA
EGP M32306 Sense: CAGTTGGTGCACAAAATACTGTCA TTGCTCAAAGCTGGCTGCCAAATGTT
Antisense: CCATTCATTTCTGCCTTCATCA
MmGl AF015224 Sense: TTCTTAACCAAACGGATGAAACTCT TGCTGTCATATATTAATTGCATAAACACCTCAACA
Antisense: GGTCTTGCAGAAAGTTAAAATAAATCAC TTG
Abbreviations: p1B¼human secretory protein p1.B; CK19¼cytokeratin 19; EGP¼human epithelial glycoprotein; MmGl¼mammaglobin.
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spreclude amplification of genomic DNA. Commercially available
primers and probes for the ‘housekeeping’ genes b-actin and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied
Biosystems) were also used.
Serially diluted cDNA synthesised from the amplified RNA of 82
snap frozen breast cancer tissues was used to generate standard
curves for control and marker gene expression. For all cDNA
dilutions, fluorescence was detected from 0 to 50 PCR cycles for
the control and marker genes in singleplex reactions, which
allowed the deduction of the CT value for each product. The CT
value (threshold cycle) is the PCR cycle at which a significant
increase in fluorescence is detected because of the exponential
accumulation of PCR products and is represented in arbitrary
units (TaqMan Universal PCR Master Mix Protocol, Applied
Biosystems) (Bieche et al, 1999). The expression of each tumour
marker gene was calculated relative to b-actin in each sample, and
the second ‘housekeeping’ gene, GAPDH, was used only to confirm
reaction efficiency. Each experiment was performed in triplicate.
Quality control measures for the PCR reactions included the
addition of a genomic DNA control and a non-template control.
Clinical follow-up
Of every patient, up to 1 February 2010, regular clinical follow-up
was recorded in the patient file and the Institute’s Medical
Registry. This included evaluation of relapse of disease, breast
cancer-related death and death by other causes. Relapse of disease
was defined as the development of either local or distant breast
cancer metastases. In case of relapse, the date of diagnosis was
recorded. In the absence of relapse, the date of the last visit to the
outpatient clinic within a year before February 2010 was recorded
as last follow-up date. When needed, for example, when the last
follow-up was longer than a year before or further treatment took
place in another hospital, information was verified with the general
physician and the last visit there was recorded as last follow-up.
One patient without relapse refused further participation after 44
months of follow-up, being longer than a year before February
2010. This date was recorded as last follow-up and censored for
further analysis.
Statistics
Analyses were carried out using SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA). All statistical tests were performed at the 5%
level of significant difference. Differences of rates between groups
were compared with either the two-sided Fisher’s exact test or
Pearson’s w
2-test or, for ordinal variables, w
2-test for trend.
Differences between groups with continuous variables were tested
by the nonparametric Mann–Whitney U-test. The quadratic
discriminant analysis (QDA) score function was calculated from
the expression data of four marker genes (CK19, p1B, EGP and
MmGl) as previously described (Hand, 1992; Bosma et al, 2002).
The QDA is a statistical approach to find the combination of
quadratic and linear functions of variables (in this case marker
genes), which leads to the optimal separation between groups (in
this case, advanced breast cancer patients and healthy volunteers).
It is a generalisation of the more familiar Fisher’s linear
discrimination analysis (LDA), which allows only linear functions
(Weigelt et al, 2004). The highest value of the healthy control
group was set as threshold value for positivity (QDA value 4
threshold: ‘QDA-positive’) and negativity (for QDA value p
threshold: ‘QDA-negative’) of other samples. This threshold was
fixed for any future study. QDA positivity indicated the presence of
tumour cells in a sample and, conversely, QDA negativity indicated
their absence. Patients with a QDA-positive or QDA-negative test
from their blood sample were defined as having a positive or
negative CTC status, respectively. The QPCR measurement and
QDA data analysis in this way offers a simple and objective
estimate of tumour cell presence in a given sample. Survival was
illustrated by Kaplan–Meier plots and compared between groups
by the log rank test. Clinicopathological factors known to be
associated with prognosis (age p45 years vs 445 years), tumour
size (T2 and T3 vs T1), lymph node involvement (yes vs no), both
following TNM 6 classification according to Union Internationale
Contre le Cancer criteria (Sobin and Wittekind, 2002), histological
grade (3 vs 1 or 2), oestrogen receptor (ER) and/or progesterone
receptor (PR) hormone receptor (both negative vs either or both
positive) and HER2 (positive¼3þ in immunohistochemistry or
in fluorescent in situ hybridisation vs negative) were tested in
univariate analysis to calculate hazard ratios (HRs), their 95%
confidence intervals (CIs) and P-value. Variables that were found
to be significant or with the HR 42.0 or o0.5 in the univariate
analysis were included in a multivariate Cox regression model to
identify those with independent prognostic information and
furthermore to calculate HRs and their 95% CIs.
RESULTS
Study inclusion and patient characteristics
A total of 82 women with early-stage breast cancer were included
and a peripheral blood sample was obtained before surgery and
before initiating adjuvant therapy. The clinical characteristics are
described in Table 2. The median age was 56 years (range: 34–86
years), 70 (85%) were 445 years, 12 (15%) had stage III disease at
diagnosis, 20 (24%) had tumours 42cm, 22 (27%) had infiltrated
axillary lymph nodes, 18 (22%) had tumours with histological
grade 3, 9 (11%) had tumours that were ER and PR negative and 28
(22%) had tumours that were HER2 positive. In total, 68 (83%) of
the patients received any type of adjuvant therapy and 14 (17%)
received trastuzumab therapy. The median time from diagnosis to
blood collection was 14 days (range: 0.0–61 days) and the median
follow-up time from sampling to ‘relapse of disease’ or ‘last follow-up’
was 51 months (range: 17–60). The median follow-up time for
patients who did not experience an event was 51 months (range:
40–60).
Circulating tumour cell detection in patient groups
In this prospective study, 16 (20%) of the 82 primary breast cancer
patients who were included had a positive QDA score (Figure 1).
The majority of patients with a QDA-positive score (12 out of 16;
75%) had a blood sample that was positive for the EGP marker
gene and at least one other marker gene (5 out of 16, 31% was EGP
and p1B positive; 4 out of 16, 25% was EGP and CK19 positive; and
3 out of 16, 19% was EGP, p1B and CK19 positive). The four other
QDA-positive patients (4 out of 16, 25%) had a blood sample that
was EGP negative but positive for both p1B and MmGl. The
sensitivity and specificity of our test was 20% (95% CI: 12–30) and
100% (95% CI: 92–100), respectively. The distribution of patient
and primary tumour tissue characteristics were not significantly
different between the CTC-positive and CTC-negative patients
(Table 2). The median age at diagnosis was 55 (range: 36–84) and
57 (range: 34–86) for the CTC-positive and CTC-negative patients,
respectively. In addition to this, a female healthy volunteer control
group (n¼45, none positive) and advanced breast cancer patients
group (n¼16; 13 (81%) positive) were tested (Figure 1). The QDA
values among advanced breast cancer patients were higher
compared with early breast cancer patients as well as with healthy
controls (Mann–Whitney U-test: both Po0.001), although there
was no significant difference between early-stage patients and
healthy controls (P¼0.123). Median QDA values (range) were
 1.16 ( 9.78 to 0.00),  1.16 ( 6.25 to 1.99) and 2.39 ( 1.16 to
3.69) for the healthy controls group, early-stage breast cancer
patients and advanced breast cancer patients, respectively. For
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sfurther analysis, patients with a zero or negative QDA were
considered ‘CTC-negative’ and patients with a positive QDA were
considered ‘CTC-positive’.
CTC status at the time of diagnosis and clinical outcome
During follow-up period of the early breast cancer patients, 12
patients (14%) experienced clinical relapse: 6 of whom were CTC
positive (38% of all CTC-positive patients), and 6 of whom were
CTC negative (9% of all CTC-negative patients; Fisher’s exact test:
P¼0.010; Table 3). One CTC-positive patient had a local relapse,
followed by distant metastasis 1 month later. The other 11 patients
had distant metastases in pleura, liver, brain, bone or in
multiple sites.
Despite the relatively short follow-up period of this prospective
study, CTC status at the time of diagnosis as determined by our
assay was a significant predictor of relapse-free survival, with a
hazard ratio of 4.72 (95% CI: 1.52–14.66, P¼0.003; Figure 2 and
Table 4). Importantly, multivariate analysis demonstrated that
CTC status at the time of diagnosis was a significant and
independent predictor of relapse-free survival (multivariate Cox
regression, multivariate hazard ratio¼5.13, P¼0.006, 95% CI:
1.62–16.31; Table 5). The 4-year relapse-free survival rates were 92
and 69% for CTC-negative and CTC-positive patients, respectively
(Figure 2).
During the follow-up period, death occurred in total in eight
patients, of which five were breast cancer related and three were by
other causes (Table 3). One death occurred in the CTC-positive
group and this was a breast cancer-related death (6% of all CTC-
positive patients) with pleural metastases. In the CTC-negative
group, four breast cancer-related deaths and three deaths by other
causes occurred (6% and 5%, respectively, of all CTC-negative
patients). The patients with breast cancer-related death had
pleural, skin, bone and liver metastases. There was no significant
Table 2 Clinical characteristics of stage I–III breast cancer patients
(n¼82), according to the CTC status
Patients (n)
Total (%),
n¼82
CTC-
negative
(within
group %),
n¼66
CTC-
positive
(within
group %),
n¼16 P-value
Age (years)
p45 12 (15) 9 (14) 3 (19) 0.694
445 70 (85) 57 (86) 13 (81)
Stage of disease
a
I 47 (57) 39 (59) 8 (50) 0.285
II 23 (28) 19 (29) 4 (25)
III 12 (15) 8 (12) 4 (25)
Tumour size
a
T1 62 (76) 51 (77) 11 (69) 0.200
T2 14 (17) 12 (18) 2 (13)
T3 3 (4) 1 (2) 2 (13)
T4 3 (4) 2 (3) 1 (6)
Node stage
a
N0 60 (73) 48 (73) 12 (75) 0.785
N1 17 (21) 14 (21) 3 (19)
N2 3 (4) 2 (3) 1 (6)
N3 2 (2) 2 (3) 0 (0)
Histological grade
Grade 1 26 (32) 22 (33) 4 (25) 0.329
Grade 2 38 (46) 31 (47) 7 (44)
Grade 3 18 (22) 13 (20) 5 (31)
Hormone receptor
Negative 9 (11) 7 (11) 2 (13) 1.00
ER and/or PR positive 72 (88) 58 (88) 14 (88)
Unknown
b 1 (1) 1 (2) 0 (0)
HER2 status
c
Negative 63 (77) 52 (79) 11 (69) 0.332
Positive 18 (22) 13 (20) 5 (31)
Unknown
b 1 (1) 1 (2) 0 (0)
Adjuvant therapy
None 14 (17) 9 (14) 5 (31) 0.581
CT 1 (1) 1 (2) 0 (0)
RT 25 (31) 22 (33) 3 (19)
HT 3 (4) 2 (3) 1 (6)
CT+RT 13 (16) 10 (15) 3 (19)
RT+HT 11 (13) 10 (15) 1 (6)
CT+RT+HT 15 (18) 12 (18) 3 (19)
Any adjuvant therapy
No 14 (17) 9 (14) 5 (31) 0.134
Yes 68 (83) 57 (86) 11 (69)
Trastuzumab therapy
No 68 (83) 54 (82 14 (88) 0.726
Yes 14 (17) 12 (18) 2 (12)
Abbreviations: CTC-positive or CTC-negative¼positive or negative circulating
tumour cell status according to quadratic discriminant analysis (QDA) score;
ER¼oestrogen receptor; PR¼progesterone receptor; HER2¼human epidermal
growth factor receptor 2; CT¼chemotherapy; RT¼radiotherapy; HT¼hormonal
therapy.
aTNM 6 classification according to the Union Internationale Contre le
Cancer criteria.
bOne patient with unknown hormone receptor and HER2 status was
excluded from Fisher’s exact test.
cHER2 positivity¼3+ in immunohistochemistry or
positive fluorescent in situ hybridisation test (FISH).
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Figure 1 Quadratic discriminant analysis (QDA) values incorporating
the expression of the four marker genes CK19, p1B, EGP and MmGl
measured in the peripheral blood of healthy controls (n¼45; open circles),
early-stage breast cancer (BC) patients (n¼82; triangles) and advanced BC
patients (n¼16; closed circles). The median expression levels for the QDA
are indicated by a horizontal line (healthy controls¼ 1.16, early-stage BC
patients¼ 1.16, advanced breast cancer patients¼2.39).
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sdifference in overall- and breast cancer-related survival between
the CTC-positive and CTC-negative group (Fisher’s exact test and
Pearson’s w
2-test: P¼1.000 and P¼0.686, respectively; Table 3).
CTC positivity was not associated with breast cancer-related or
overall survival with a hazard ratio of 1.02 (95% CI: 0.11–9.09,
P¼0.989) and 0.57 (95% CI: 0.07–4.63, P¼0.594), respectively.
The 4-year overall survival rates were 91 and 94% for CTC-negative
and CTC-positive patients, respectively.
Additional analyses: effect of frozen storage and the value
of repeated sampling after therapy
We assessed the effect of frozen storage in eight early-stage and
one advanced breast cancer patients and five healthy controls. All
samples had a concordant CTC status in both the fresh and stored
sample.
We also used the assay in peripheral blood samples of a subset
of patients who were CTC negative at diagnosis and had remained
disease free. Of the 45 women who participated, 40 women tested
CTC negative and 5 women (5 out of 45 (11%)) tested CTC
positive, currently without experiencing a diagnosed relapse of
disease. During follow-up (median time from second blood
collection to last follow-up: 6.2 months; range: 0.0–13) no relapses
or deaths occurred.
DISCUSSION
An optimised CTC assay was used to estimate circulating tumour
cell load in prospectively collected peripheral blood samples of 82
early-stage and 16 advanced breast cancer patients and 45 healthy
female controls. In early-stage breast cancer patients, the
sensitivity of our assay was 20%. Based on the data from several
published studies with early-stage breast cancer patients (Pierga
et al, 2008; Rack et al, 2008; Daskalaki et al, 2009; Xenidis et al,
2009; Krishnamurthy et al, 2010; Riethdorf et al, 2010) the assay’s
sensitivity was found to be comparable with other assays with high
specificity, except for Daskalaki et al (2009) who found a higher
sensitivity of 52.4% with a specificity of 97.8% in a study that had
only included stage I and II breast cancer patients. The CellSearch
system (Veridex, Warren, NJ, USA) is one of the most used and
validated commercial CTC detection platforms currently available
(Allard et al, 2004; Balic et al, 2005; Cristofanilli et al, 2007;
Riethdorf et al, 2007; Krishnamurthy et al, 2010). This method was
used in the recent GeparQuattro clinical trial where CTCs were
prospectively monitored in neo-adjuvant therapy. Here, at baseline
a sensitivity of 21.6% was found for CTC positivity, using a cutoff
of X1 CTC/7.5ml peripheral blood (Riethdorf et al, 2010). While
generally demonstrating a similar sensitivity and specificity to the
CellSearch system, our assay offers several other advantages: first,
our assay is objective, as an algorithm generates a single score
automatically for determining CTC positivity based on tumour
marker gene expression levels detected by QPCR. This is in
Table 3 Incidence of relapses and overall and breast cancer-related
deaths in early breast cancer patients, in total and according to CTC status
at diagnosis
Patients (n)
Total (%),
n¼82
CTC-
negative
(within
group %),
n¼66
CTC-
positive
(within
group %),
n¼16 P-value
Relapse of disease
No 70 (85) 60 (91) 10 (63) 0.010
Yes 12 (15) 6 (9) 6 (38)
Overall survival
Alive 74 (90) 59 (89) 15 (94) 1.000
Death 8 (10) 7 (11) 1 (6)
Breast cancer-related survival
Alive 74 (90) 59 (89) 15 (94) 0.686
Death, breast cancer related 5 (6) 4 (6) 1 (6)
Death, other cause 3 (4) 3 (5) 0 (0)
Abbreviation: CTC-positive or CTC-negative¼positive or negative circulating
tumour cell status according to quadratic discriminant analysis (QDA) score.
Significant P-values are shown in bold.
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Figure 2 Kaplan–Meier survival curve for relapse-free survival of early-
stage breast cancer patients (n¼82) who were CTC negative (n¼66) or
positive (n¼16) at diagnosis. CTC-positive patients had a significantly
poorer relapse-free survival than CTC-negative patients (univariate hazard
ratio¼4.72; 95% CI: 1.52–14.66; log rank test P¼0.003). The number of
patients at risk at each time point (months) are indicated for the CTC-
negative (black) and CTC-positive (grey) groups. Abbreviations: CTC-
positive or CTC-negative¼positive or negative circulating tumour cell
status according to quadratic discriminant analysis (QDA) score;
FU¼follow-up.
Table 4 Univariate analysis of relapse-free survival by CTC positivity and common clinical variables
Parameter Hazard ratio 95% CI P-value Cox regression: P-value
CTC (positive vs negative), n¼82 4.72 1.52–14.66 0.007 0.003
Age (o45 years vs 445 years), n¼82 1.22 0.27–5.58 0.797 0.797
Tumour size (XT2 vs T1), n¼82
a 3.40 1.10–10.55 0.034 0.025
Node stage (N+ vs N0), n¼82
a 1.40 0.42–4.65 0.586 0.584
Histological grade (grade 3 vs 1 and 2), n¼82 1.19 0.32–4.39 0.798 0.798
Hormone receptor negative vs positive, n¼81 3.04 0.82–11.25 0.096 0.080
HER2 positive vs negative, n¼81 1.17 0.32–4.31 0.818 0.817
Abbreviations: CI¼confidence interval; CTC-positive¼positive circulating tumour cell status according to quadratic discriminant analysis (QDA) score; HER2¼human
epidermal growth factor receptor 2.
aTNM 6 classification according to the Union Internationale Contre le Cancer criteria. Significant P-values are shown in bold.
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determined to be CTCs by software and need to be manually
confirmed by an operator. This step can introduce subjectivity in
scoring, which is significant when as few as one or two cells in
a sample are sufficient to class the patient as ‘CTC-positive’.
Recently, Kraan et al (2011) observed that image interpretation
was the main contributor to between-laboratory variation. In
addition, our assay is considerably less expensive, costing less than
US$25 per sample, compared with approximately US$600 per
sample for the CellSearch system (Kaiser, 2010). Finally, there
already exists an equipment for the automation of the enrichment,
cDNA preparation and QPCR steps in our assay, and hence it could
potentially require little manual work or technical knowledge.
Although this is a preliminary study and further validation
involving additional patients would be required to confirm that
an automated system could provide equivalent prognostic data,
there is a potential for the use of such system in a clinical setting.
The threshold for QDA positivity was set at the highest QDA
value in the healthy controls group, resulting in 100% specificity,
as previously described (Bosma et al, 2002; Weigelt et al, 2003).
Although our assay’s sensitivity could have been augmented by
lowering the threshold, priority was given to avoid false positives.
In total, 81% of the advanced patients assayed were CTC positive
vs 0% of the healthy controls (Figure 1). We hypothesised that
enriching a sample for tumour cells before assessing tumour
marker gene expression would be beneficial for assay sensitivity,
and this appears to be the case. We had previously demonstrated
that when tumour cell enrichment was not performed, 30% of
advanced patients assayed from a similarly selected patient group
had a positive QDA score indicating CTC positivity vs 0% of
healthy controls (Weigelt et al, 2003). We also had previously
shown that using a positive enrichment strategy for cells
expressing both EpCam and ErbB2 antigens resulted in the
detection of higher levels of tumour marker gene expression than
enriching for cells expressing just one of the antigens (Molloy et al,
2008). Also, the multimarker gene expression panel used has
obvious benefits over the use of a single marker for the detection of
tumour cells. Finally, the use of the quadratic discriminant score
function is not prone to subjectivity in scoring or inaccuracies in
quantitation as immunohistochemical staining or densitometry of
an electrophoresed nucleic acid band can be.
Our platform also has limitations using immunomagnetic bead
selection with antibodies directed at EpCam and ErbB2. This may
very well also have caused a bias by not selecting any potential
EpCam and ErbB2 non- or low-expressing cells. It is believed that
CTCs may lose EpCam in order to intravasate and to reach
circulation, in a process called epithelial-to-mesenchymal transi-
tion (EMT) (Bonnomet et al, 2010). Indeed, Sieuwerts et al (2009)
showed that a subtype of breast cancer cells is not detected in the
EpCam-based CellSearch assay. Consistent with this hypothesis, in
the present study, blood samples of 17 early-stage EGP-negative
patients were found positive for one or more of the other three
marker genes (data not shown). These studies and our data
confirm that indeed there may be phenotypic differences between
CTCs.
Our previous study using non-tumour cell-enriched blood
samples from advanced patients demonstrated that CTC status
was an independent predictor of both progression-free and overall
survival (Weigelt et al, 2003). The CTC positivity as determined by
our assay was a significant predictor of relapse-free survival in the
primary breast cancer patient cohort (multivariate HR¼5.13,
P¼0.006, 95% CI: 1.62–16.31; Table 5). Importantly, multivariate
analyses demonstrated that CTC status provided significant
prognostic information that was independent of other commonly
used clinical variables, including age at diagnosis, lymph node
status, histological grade, hormone receptor status and HER2
status (Tables 4 and 5). Tumour size, which is known for its
prognostic value, did not reach statistical significance in our
analysis. In contrast to predicting for relapse, CTC positivity was
not a predictor for breast cancer-related or overall survival. Others
have demonstrated a significantly reduced survival for CTC-
positive early-stage breast cancer patients (Rack et al, 2008;
Daskalaki et al, 2009; Xenidis et al, 2009). The observation that
CTC positivity did not predict for survival in the present study
may be because of the combination of a follow-up time that was
relatively short for the observation of deaths and the occurrence of
a limited number of events, being eight deaths in total.
Additional exploratory analyses of our assay on the effect of
frozen storage, which found concordant results in all samples,
indicated the possibility to store freshly collected samples for a
longer period and to process them later. If confirmed on a larger
scale, this method would greatly facilitate sample collection and
would present another advantage to other methods described
earlier (Daskalaki et al, 2009), including the CellSearch system in
which samples are required to be processed within 72h (Riethdorf
et al, 2007). The analysis on the value of repeated sampling after
therapy did not show relevance during the relatively short follow-
up, and the prospective value of this second sampling will be
studied in the future in ongoing follow-up.
In conclusion, we have demonstrated a sensitive and specific
platform for the detection of circulating tumour cells in both
advanced and early-stage breast cancer patients. In this study with
early-stage breast cancer patients, we found that our assay was
prognostic for relapse-free survival. Further work will be required
in prospective trials to fully determine whether our assay can be
used to improve disease outcome in patients who are CTC positive.
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